<DOC>
	<DOCNO>NCT00383136</DOCNO>
	<brief_summary>The elective ( `` standard care '' ) treatment ST - elevation acute myocardial infarction ( STEMI ) currently consist primary angioplasty stent implantation administration Abciximab , inhibitor GP IIb/IIIa platelet receptor . Tirofiban another potent inhibitor GP IIb/IIIa platelet receptor efficacy platelet aggregation inhibition equal great Abciximab high dose bolus use , i.e . 25 microg/kg , ( platelet aggregation inhibition &gt; 90 % 15 minute infusion ) . It therefore hypothesize drug improve result primary angioplasty extent Abciximab . The aim study compare efficacy , term myocardial reperfusion index , Abciximab high dose Tirofiban primary angioplasty STEMI , case treatment transfer treatment catheterization laboratory procedure . The reference hypothesis study objective equivalence non-inferiority Tirofiban respect Abciximab .</brief_summary>
	<brief_title>FATA : Randomized Study Facilitated Angioplasty With Tirofiban Abciximab</brief_title>
	<detailed_description>The Facilitated Angioplasty Tirofiban Abciximab Study ( FATA Study ) prospective multicentre study , randomize 2 group ( high dose Tirofiban Abciximab ) , sample 700 patient acute myocardial infarction primary angioplasty indicate . Patients enrol Emergency Room Intensive Care Unit hospital department externally event intervention Emergency Ambulance Service 118 . For patient must possible administer IIb/IIIa inhibitor immediately ECG clinical diagnosis , transfer cath lab primary angioplasty procedure . Patients arrive directly cath lab without randomize transfer also include . Major exclusion criterion : Complete leave bundle branch block , Previous myocardial infarction site , Post-anoxic coma , Known thrombocytopenia leucopenia , Previous episodes hemorrhagic diathesis allergy ASA thienopyridine ; Anticoagulant therapy dicumarol INR &gt; 2 ; Previous treatment thrombolytic ( within previous 48 hour ) . Randomization take place soon possible diagnostic ECG perform mean centralize automatic system use SMS message send ordinary cell phone . The primary endpoint ST resolution 90 minute open affected vessel . Secondary endpoint include : Patency vessel first selective angiography , reflow phenomenon procedure , TIMI 3 flow end procedure , MACE ( death , reinfarction* , urgent TVR° ) 30 day , MACE ( death , reinfarction* , TVR° ) 6 month , major bleed require transfusion surgery , reduction Hb 5 g % , Ictus intracranial hemorrhage . To demonstrate study hypothesis , i.e . Tirofiban equivalent Abciximab facilitate primary angioplasty acute myocardial infarction , sufficient statistical significance , necessary number patient drug calculate basis method use equivalence study fix 350 pt per group . 390 patient randomize ( Sept 15th , 2006 ) . Results expect end 2007 . This study establish whether primary angioplasty high dose Tirofiban equivalent effect Abciximab , first term microcirculation protection long-term clinical result . If hypothesis confirm , Tirofiban could use alternative Abciximab , considerable saving give much low cost .</detailed_description>
	<mesh_term>Infarction</mesh_term>
	<mesh_term>Myocardial Infarction</mesh_term>
	<mesh_term>Abciximab</mesh_term>
	<mesh_term>Tirofiban</mesh_term>
	<mesh_term>Antibodies , Monoclonal</mesh_term>
	<mesh_term>Immunoglobulin Fab Fragments</mesh_term>
	<criteria>1 . STEMI diagnose due presence chest pain last least 20 minute less 6 hour , associate elevation ST segment &gt; 1 mm least 2 adjacent lead 2 . Informed consent 3 . Age &gt; 18 year 1 . Complete leave bundle branch block 2 . Previous myocardial infarction site 3 . Postanoxic coma 4 . Known thrombocytopenia leucopenia 5 . Severe hepatic dysfunction ; 6 . Previous episode hemorrhagic diathesis allergy ASA thienopyridine ; 7 . Recent major surgery ( &lt; 3 month ) 8 . Associated disease involve short life expectancy ( &lt; 2 year ) ; 9 . Arterial hypertension ( AP &gt; 180/110 ) ; 10 . Positive case history stroke within previous 30 day ; 11 . Positive case history intracranial disease ( aneurysm , arterovenous malformation ) ; 12 . Major trauma within previous six week ; 13 . A clinical condition , doctor 's opinion , could interfere patient 's full participation study ; 14 . Pregnancy fertile age ; 15 . Anticoagulant therapy dicumarol INR &gt; 2 ; 16 . Renal insufficiency ( creatinine &gt; 3.0 mg/dl ) know time study ; 17 . Previous treatment thrombolytic ( within previous 48 hour ) ; 18 . Participation study progress .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2008</verification_date>
	<keyword>STEMI</keyword>
	<keyword>Primary Angioplasty</keyword>
	<keyword>Abciximab</keyword>
	<keyword>Tirofiban</keyword>
</DOC>